Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prospective, population-based study of an 8-year follow up. To determine the direct cost of diabetic retinopathy [DR], evaluating our screening programme and the cost of treating DR, focusing on diabetic macular oedema [DMO] after anti-vascular endothelial growth factor [anti-VEGF] treatment. METHODS: A total of 15,396 diabetes mellitus [DM] patients were studied. We determined the cost-effectiveness of our screening programme against an annual programme by applying the Markov simulation model. We also compared the cost-effectiveness of anti-VEGF treatment to laser treatment for screened patients with DMO. RESULTS: The cost of our 2.5-year screening programme was as follows: per patient with any-DR, €482.85 ± 35.14; per sight-threatening diabetic retinopathy [STDR] patient, €1528.26 ± 114.94; and €1826.98 ± 108.26 per DMO patient. Comparatively, an annual screening programme would result in increases as follows: 0.77 in QALY per patient with any-DR and 0.6 and 0.44 per patient with STDR or DMO, respectively, with an incremental cost-effective ratio [ICER] of €1096.88 for any-DR, €4571.2 for STDR and €7443.28 per DMO patient. Regarding diagnosis and treatment, the mean annual total cost per patient with DMO was €777.09 ± 49.45 for the laser treated group and €7153.62 ± 212.15 for the anti-VEGF group, with a QALY gain of 0.21, the yearly mean cost was €7153.62 ± 212.15 per patient, and the ICER was €30,361. CONCLUSIONS: Screening for diabetic retinopathy every 2.5 years is cost-effective, but should be adjusted to a patient's personal risk factors. Treatment with anti-VEGF for DMO has increased costs, but the cost-utility increases to 0.21 QALY per patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455 · cited 1×
“5year programme [6].”
Screening for Presence or Absence of Diabetic Retinopathy: A Meta-analysis
Bragge, P. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.319 · Cited by 134 · cited 1×
“To diagnose DR, the use nonmydriatic fundus retinography and telemedicine [3].”
MethodAgardh, E., & Tababat-Khani, P. (2011) · Diabetes Care · doi:10.2337/dc10-2308 · Cited by 113
Cited by
Giri, B., Dey, S., Das, T., Sarkar, M., Banerjee, J., & Dash, S. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.157 · Cited by 635
Diabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
Tóth, G., Limburg, H., Szabó, D., Sándor, G. L., Nagy, Z. Z., & Németh, J. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316337 · Cited by 11
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Ruiz-Moreno, J. M., Gámez Lechuga, M., Calvo, P., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Abraldes, M. J. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00959-2 · Cited by 7
Economic Aspects in the Management of Diabetic Macular Edema in Italy
Calabrò, G. E., Basile, M., Varano, M., Amore, F., Ricciardi, R., Bandello, F., & Cicchetti, A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.938987 · Cited by 4
Metadata
- Authors
- Romero-Aroca, P., de la Riva-Fernandez, S., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., Soler, N., & Puig, D.
- Venue
- BMC Ophthalmology
- Published
- 2016-08-04
- Volume
- 16
- Issue
- 1
- Pages
- 136-136
- ISSN
- 1471-2415 (ISSN-L)
- OpenAlex
- W2490360718
- Cited by
- 46
- References
- 4
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. https://app.cochat.ai/papers/10.1186/s12886-016-0318-x
- The paper
- Romero-Aroca, P., de la Riva-Fernandez, S., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., Soler, N., & Puig, D. (2016). Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmology. https://doi.org/10.1186/s12886-016-0318-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.